HAEMATOLOGICA

Scope & Guideline

Advancing Hematology: Where Research Meets Impact

Introduction

Delve into the academic richness of HAEMATOLOGICA with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0390-6078
PublisherFERRATA STORTI FOUNDATION
Support Open AccessYes
CountryItaly
TypeJournal
Convergefrom 1947 to 2024
AbbreviationHAEMATOLOGICA / Haematologica
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY

Aims and Scopes

HAEMATOLOGICA focuses on advancing the understanding and treatment of hematological conditions through innovative research methodologies and clinical studies. The journal aims to disseminate high-quality research that contributes to the field of hematology, including but not limited to leukemia, lymphoma, and related disorders.
  1. Clinical and Translational Research:
    HAEMATOLOGICA emphasizes clinical trials and translational studies that bridge laboratory findings with patient care, aiming to improve treatment protocols and patient outcomes in hematological malignancies.
  2. Molecular and Genomic Insights:
    The journal explores the genomic landscapes and molecular mechanisms underlying hematological diseases, providing insights into targeted therapies and their efficacy.
  3. Innovative Treatment Modalities:
    Research on new treatment strategies, including immunotherapy, CAR T-cell therapy, and novel pharmaceuticals, is a core focus, reflecting the journal's commitment to advancing therapeutic options for hematological patients.
  4. Patient-Centric Studies:
    The journal includes studies that assess quality of life and treatment adherence among patients, ensuring that research is aligned with the needs and experiences of individuals affected by blood disorders.
  5. Epidemiological and Public Health Perspectives:
    HAEMATOLOGICA also addresses the epidemiology of hematological diseases, including the impact of socio-economic factors and healthcare access on disease outcomes.
HAEMATOLOGICA has shown a robust evolution in its research themes, with several emerging topics gaining traction. These trends reflect the journal's responsiveness to new challenges and innovations in hematology.
  1. Immunotherapy and Targeted Therapies:
    There is a significant increase in studies focusing on immunotherapy, including CAR T-cell therapy and bispecific antibodies, as well as targeted therapies that aim to exploit specific genetic alterations in hematological malignancies.
  2. Minimal Residual Disease Monitoring:
    The importance of monitoring minimal residual disease (MRD) has gained prominence, with research focusing on its prognostic implications and its role in treatment decisions.
  3. Socioeconomic Factors and Health Disparities:
    Emerging research on how socioeconomic factors impact treatment outcomes and access to care in hematological malignancies is becoming more prevalent, highlighting the journal's commitment to patient-centered research.
  4. Microbiome and Hematology:
    Studies exploring the relationship between the microbiome and hematological diseases have emerged, reflecting a growing interest in how gut health may influence treatment responses and disease progression.
  5. Long-Term Outcomes and Survivorship:
    Research focusing on the long-term health outcomes and quality of life of hematology patients, particularly survivors of hematological malignancies, is increasingly featured, indicating a shift towards holistic patient care.

Declining or Waning

While HAEMATOLOGICA continues to thrive in various research areas, some themes have shown a decline in focus over recent years. This may indicate a shifting interest towards more contemporary issues or advancements in the field.
  1. Traditional Chemotherapy Studies:
    There has been a noticeable decrease in studies focusing solely on traditional chemotherapy regimens, as the field shifts towards exploring novel therapies and combinations that enhance efficacy and minimize toxicity.
  2. Basic Research Without Clinical Application:
    Studies that do not translate into clinical applications or lack direct relevance to patient outcomes are less frequently published, reflecting a trend towards more impactful research.
  3. Single-Agent Drug Studies:
    Research centered on single-agent therapies has waned, likely due to the increasing complexity of treatment regimens that involve combination therapies and personalized medicine.
  4. Elderly Patient Studies:
    Research specifically targeting elderly populations in hematology appears to be less prevalent, suggesting a potential gap in understanding the unique challenges faced by this demographic.

Similar Journals

Blood Cancer Discovery

Uncovering Breakthroughs in Blood Cancer Science
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

Clinical Lymphoma Myeloma & Leukemia

Empowering Oncology Through Rigorous Scholarship
Publisher: CIG MEDIA GROUP, LPISSN: 2152-2650Frequency: 6 issues/year

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

CURRENT OPINION IN HEMATOLOGY

Transforming contemporary issues into clinical solutions.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1065-6251Frequency: 6 issues/year

CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.

ACTA HAEMATOLOGICA

Driving Excellence in Blood Science Research
Publisher: KARGERISSN: 0001-5792Frequency: 6 issues/year

ACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.

ANNALS OF HEMATOLOGY

Empowering the scientific community with quality contributions.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

Hematologie

Advancing the Science of Blood Disorders
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.

SEMINARS IN HEMATOLOGY

Elevating Clinical Practices with Cutting-Edge Knowledge.
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0037-1963Frequency: 4 issues/year

SEMINARS IN HEMATOLOGY, published by W B SAUNDERS CO-ELSEVIER INC, stands as a premier academic journal dedicated to the field of hematology. Established in 1964, this journal has built a robust reputation over its nearly six-decade history, now recognized as a Q1 journal in Hematology with an impressive impact factor reflective of its high relevance and citation frequency within the academic community. Residents and scholars can access meticulously curated articles that address innovative research, clinical practices, and advancements in the understanding of blood disorders and treatment methodologies. The journal, ranked #36 out of 137 in the Scopus Medicine Hematology category, showcases cutting-edge research, ensuring its contributions are crucial for professionals, researchers, and students striving to stay at the forefront of the hematology field. Although not an Open Access journal, SEMINARS IN HEMATOLOGY continues to unite a global audience dedicated to advancing the science and clinical practices in hematology.

EUROPEAN JOURNAL OF HAEMATOLOGY

Bridging Science and Practice in Blood Disorder Management
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

Hematology-American Society of Hematology Education Program

Empowering Knowledge in Blood Disorders
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Indian Journal of Hematology and Blood Transfusion

Transforming Blood Health: Where Research Meets Practice
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.